Adverse Drug Events (ADEs) pose an under-recognized public health threat, accounting for an estimated one-third of U.S. hospital adverse events and one million emergency department visits annually. The Department of Health and Human Services (HHS) convened a Steering Committee on ADEs, which led to the development of the National Action Plan for Adverse Drug Event Prevention. This Plan recognizes the significant threat posed by ADEs and identifies federal efforts to date to measure and prevent ADEs with recommendations for continued focused efforts to combat this rising issue.
On November 12, three speakers from the CDC and CMS will provide a summary of the National Action Plan and how pharmacists and other clinicians can take steps to prevent harm to patients from the medications most commonly involved in ADEs. The presenters, Mary A. Andrawis, PharmD, MPH; Andrew Geller, MD, LCDR, USPHS; and Nadine Shehab, PharmD, MPH, will also address the issues surrounding high-risk patient populations and high-risk settings and situations that may require particular attention from pharmacists.
The three most common, clinically significant, preventable and measurable types of ADE identified by the National Action Plan were associated with anticoagulants (bleeding), diabetes agents (hypoglycemia) and opioid analgesics (accidental overdoses, oversedation and respiratory depression).
The National Action Plan outlines a four-pronged approach to minimizing the harm associated with these common ADEs through surveillance, prevention, incentives and oversight, and research. The webinar will focus on the role of pharmacists in this initiative, particularly in surveillance within their hospitals and prevention efforts.